First Wave BioPharma Announces Phase 2 Adrulipase Combination Trial Data to be Presented at the 2023 Digestive Disease Week (DDW) Conference
February 21, 2023 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
AzurRx BioPharma Announces Positive Interim Data From First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
August 11, 2020 16:01 ET
|
AzurRx BioPharma, Inc.
Data from first five patients demonstrate positive results with primary efficacy and secondary safety endpoints achievedClinically meaningful improvement (>80%) in coefficient of fat absorption...